CoChat

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum

Open access
Meeter, Lieke H.H., Vijverberg, Everard G., Del Campo, Marta, Rozemuller, Annemieke J.M., Donker Kaat, Laura, de Jong, Frank Jan, van der Flier, Wiesje M., Teunissen, Charlotte E., van Swieten, John C., Pijnenburg, Yolande A.L. · 2018 · Neurology

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To examine the clinical value of neurofilament light chain (NfL) and the phospho-tau/total tau ratio (p/t-tau) across the entire frontotemporal dementia (FTD) spectrum in a large, well-defined cohort. METHODS: CSF NfL and p/t-tau levels were studied in 361 patients with FTD: 179 behavioral variant FTD, 17 FTD with motor neuron disease (FTD-MND), 36 semantic variant primary progressive aphasia (PPA), 19 nonfluent variant PPA, 4 logopenic variant PPA (lvPPA), 42 corticobasal syndrome, and 64 progressive supranuclear palsy. Forty-five cognitively healthy controls were also included. Definite pathology was known in 68 patients (49 frontotemporal lobar degeneration [FTLD]-TDP, 18 FTLD-tau, 1 FTLD-FUS). RESULTS: NfL was higher in all diagnoses, except lvPPA (n = 4), than in controls, equally elevated in behavioral variant FTD, semantic variant PPA, nonfluent variant PPA, and corticobasal syndrome, and highest in FTD-MND. The p/t-tau was lower in all clinical groups, except lvPPA, than in controls and lowest in FTD-MND. NfL did not discriminate between TDP and tau pathology, while the p/t-tau ratio had a good specificity (76%) and moderate sensitivity (67%). Both high NfL and low p/t-tau were associated with poor survival (hazard ratio on tertiles 1.7 for NfL, 0.7 for p/t-tau). CONCLUSION: NfL and p/t-tau similarly discriminated FTD from controls, but not between clinical subtypes, apart from FTD-MND. Both markers predicted survival and are promising monitoring biomarkers for clinical trials. Of note, p/t-tau, but not NfL, was specific to discriminate TDP from tau pathology in vivo. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with cognitive issues, CSF NfL and p/t-tau levels discriminate between those with and without FTD spectrum disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000005261

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 NfL and p/t-tau ratio levels by clinical diagnosis and by underlying pathology (A) NfL levels and (C) the p/t-tau ratio in clinical FTD subgroups; patients with confirmed underlying pathology are depicted in black. (B) NfL levels and (D) the p/t-tau ratio in patients with known underlying pathology based on autopsy-confirmed pathology (FTLD-tau = blue circles; PSP = red squares; CBD = gray filled upward triangles; FTLD-TDP = aqua upward triangles) or a known pathogenic mutation (MAPT = filled light-purple squares, GRN = filled blue downward triangles, C9orf72 repeat expansion = purple filled diamonds; OPTN = green diamonds); a low p/t-tau ratio (cut-off ≤ 0.121, dashed line) discriminated FTLD-TDP from FTLD-tau with a specificity of 76% and a sensitivity of 67%. Horizontal lines represent means. ***p < 0.001; **p < 0.01; *(A) higher NfL or (C) lower p/t-tau ratio compared with controls; a = (A) lower NfL or (C) higher p/t-tau ratio compared with FTD-MND, b = (A) higher NfL or (C) lower p/t-tau ratio compared with PSP. bvFTD = behavioral variant frontotemporal dementia; CBD = corticobasal degeneration; CBS = corticobasal syndrome; FTD-MND = frontotemporal dementia with concomitant motor neuron disease; FTLD-tau = frontotemporal lobar degeneration with tau inclusions; FTLD-TDP = frontotemporal lobar degeneration with TAR DNA-binding protein 43 inclusions; lvPPA = logopenic variant primary progressive aphasia; NfL = neurofilament light chain; nfvPPA = nonfluent variant primary progressive aphasia; ns = not significant; PSP = progressive supranuclear palsy; p/t-tau = phospho-tau/total tau; svPPA = semantic variant primary progressive aphasia.
Figure 1 NfL and p/t-tau ratio levels by clinical diagnosis and by underlying pathology (A) NfL levels and (C) the p/t-tau ratio in clinical FTD subgroups; patients with confirmed underlying pathology are depicted in black. (B) NfL levels and (D) the p/t-tau ratio in patients with known underlying pathology based on autopsy-confirmed pathology (FTLD-tau = blue circles; PSP = red squares; CBD = gray filled upward triangles; FTLD-TDP = aqua upward triangles) or a known pathogenic mutation (MAPT = filled light-purple squares, GRN = filled blue downward triangles, C9orf72 repeat expansion = purple filled diamonds; OPTN = green diamonds); a low p/t-tau ratio (cut-off ≤ 0.121, dashed line) discriminated FTLD-TDP from FTLD-tau with a specificity of 76% and a sensitivity of 67%. Horizontal lines represent means. ***p < 0.001; **p < 0.01; *(A) higher NfL or (C) lower p/t-tau ratio compared with controls; a = (A) lower NfL or (C) higher p/t-tau ratio compared with FTD-MND, b = (A) higher NfL or (C) lower p/t-tau ratio compared with PSP. bvFTD = behavioral variant frontotemporal dementia; CBD = corticobasal degeneration; CBS = corticobasal syndrome; FTD-MND = frontotemporal dementia with concomitant motor neuron disease; FTLD-tau = frontotemporal lobar degeneration with tau inclusions; FTLD-TDP = frontotemporal lobar degeneration with TAR DNA-binding protein 43 inclusions; lvPPA = logopenic variant primary progressive aphasia; NfL = neurofilament light chain; nfvPPA = nonfluent variant primary progressive aphasia; ns = not significant; PSP = progressive supranuclear palsy; p/t-tau = phospho-tau/total tau; svPPA = semantic variant primary progressive aphasia.CC BY-NC-ND · PubMed Central
Figure 2 Association between NfL and the p/t-tau ratio In (A) the clinical diagnoses are marked: controls (blue filled circles), bvFTD (purple filled squares), FTD-MND (gray filled upward triangles), svPPA (aqua filled downward triangles), nfvPPA (blue filled diamonds), lvPPA (black circles), CBS (green squares), and PSP (orange triangles). In (B) the association in definite diagnoses is shown: FTLD-TDP pathology (blue upward triangles), FTLD-tau pathology (purple downward triangles), controls (gray circles), and patients without a definite diagnosis (gray squares). bvFTD = behavioral variant frontotemporal dementia; CBS = corticobasal syndrome; FTD = frontotemporal dementia; FTD-MND = frontotemporal dementia with concomitant motor neuron disease; FTLD-tau = frontotemporal lobar degeneration with tau inclusions; FTLD-TDP = frontotemporal lobar degeneration with TAR DNA-binding protein 43 inclusions; lvPPA = logopenic variant primary progressive aphasia; NfL = neurofilament light chain; nfvPPA = nonfluent variant primary progressive aphasia; PSP = progressive supranuclear palsy; p/t-tau = phospho-tau/total tau; svPPA = semantic variant primary progressive aphasia.
Figure 2 Association between NfL and the p/t-tau ratio In (A) the clinical diagnoses are marked: controls (blue filled circles), bvFTD (purple filled squares), FTD-MND (gray filled upward triangles), svPPA (aqua filled downward triangles), nfvPPA (blue filled diamonds), lvPPA (black circles), CBS (green squares), and PSP (orange triangles). In (B) the association in definite diagnoses is shown: FTLD-TDP pathology (blue upward triangles), FTLD-tau pathology (purple downward triangles), controls (gray circles), and patients without a definite diagnosis (gray squares). bvFTD = behavioral variant frontotemporal dementia; CBS = corticobasal syndrome; FTD = frontotemporal dementia; FTD-MND = frontotemporal dementia with concomitant motor neuron disease; FTLD-tau = frontotemporal lobar degeneration with tau inclusions; FTLD-TDP = frontotemporal lobar degeneration with TAR DNA-binding protein 43 inclusions; lvPPA = logopenic variant primary progressive aphasia; NfL = neurofilament light chain; nfvPPA = nonfluent variant primary progressive aphasia; PSP = progressive supranuclear palsy; p/t-tau = phospho-tau/total tau; svPPA = semantic variant primary progressive aphasia.CC BY-NC-ND · PubMed Central
Figure 3 Association of NfL and the p/t-tau ratio with survival Kaplan-Meier curves of (A) NfL levels stratified to tertiles: lowest (green line; NfL <1,989 pg/mL), middle (blue line; NfL 1,989–3,675 pg/mL), or highest (red line; NfL >3,675 pg/mL); and (B) the p/t-tau ratio stratified into lowest (green line, ratio <0.115), middle (blue line, ratio 0.115–0.146), or highest (red line, ratio >0.146) tertiles. Vertical ticks represent living patients. *Corrected for age, sex, disease duration, and motor neuron disease. CI = confidence interval; NfL = neurofilament light chain; p/t-tau = phospho-tau/total tau.
Figure 3 Association of NfL and the p/t-tau ratio with survival Kaplan-Meier curves of (A) NfL levels stratified to tertiles: lowest (green line; NfL <1,989 pg/mL), middle (blue line; NfL 1,989–3,675 pg/mL), or highest (red line; NfL >3,675 pg/mL); and (B) the p/t-tau ratio stratified into lowest (green line, ratio <0.115), middle (blue line, ratio 0.115–0.146), or highest (red line, ratio >0.146) tertiles. Vertical ticks represent living patients. *Corrected for age, sex, disease duration, and motor neuron disease. CI = confidence interval; NfL = neurofilament light chain; p/t-tau = phospho-tau/total tau.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 122

Metadata

Authors
Meeter, L. H. H., Vijverberg, E. G., Del Campo, M., Rozemuller, A. J. M., Donker Kaat, L., de Jong, F. J., van der Flier, W. M., Teunissen, C. E., van Swieten, J. C., & Pijnenburg, Y. A. L.
Affiliations
  • Erasmus MC (NL)
  • From the Alzheimer Center and Department of Neurology (L.H.H.M., L.D.K., F.J.d.J., J.C.v.S.), Erasmus Medical Center, Rotterdam; Alzheimer Center and Department of Neurology (E.G.V., W.M.v.d.F., Y.A.L.P.), Neurochemistry Laboratory, Department of Clinical Chemistry (M.D.C., C.E.T.), Department of Pathology (A.J.M.R.), and Department of Clinical Genetics (J.C.v.S.), Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
Corresponding author
Meeter, Lieke H.H.
Venue
Neurology
Published
2018-04-03
Volume
90
Issue
14
Pages
e1231-e1239
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2790169598
Cited by
122
References
42
Citations by year
2026: 5 · 2025: 11 · 2024: 12 · 2023: 9 · 2022: 27 · 2021: 14 · 2020: 12 · 2019: 24 · 2018: 8
FWCI
11.41
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Neurology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
ZonMw (733051024)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
frontotemporal dementia, neurofilament light chain, cerebrospinal fluid biomarkers, behavioral variant frontotemporal dementia, primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy, tau pathology, survival prediction, disease progression monitoring
MeSH terms
Aged, Female, Humans, Male, Middle Aged, Phosphorylation, Prognosis, Sensitivity and Specificity, Supranuclear Palsy, Progressive, Cohort Studies, Biomarkers, Case-Control Studies, Motor Neuron Disease, tau Proteins, Neurofilament Proteins, Aphasia, Primary Progressive, Kaplan-Meier Estimate, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. https://app.cochat.ai/papers/10.1212/wnl.0000000000005261
The paper
Meeter, L. H. H., Vijverberg, E. G., Del Campo, M., Rozemuller, A. J. M., Donker Kaat, L., de Jong, F. J., van der Flier, W. M., Teunissen, C. E., van Swieten, J. C., & Pijnenburg, Y. A. L. (2018). Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. https://doi.org/10.1212/wnl.0000000000005261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.